Meilun: What does the four-channel blood coagulation analyzer measure? What is the development prospect of the industry?

The detection of thrombus and hemostasis has developed from traditional manual methods to fully automated coagulation analysis, and from a single coagulation method to immunological and biochemical methods. The detection of thrombus and hemostasis has become more convenient and accurate. The use of coagulation analysis for hemostasis and thrombosis laboratory examinations can provide valuable indicators for the diagnosis and differential diagnosis of hemorrhagic and thrombotic diseases, the monitoring of thrombolysis and anticoagulation therapy and the observation of therapeutic effects. Meilun

The blood coagulation market is a very fast-growing IVD segment in recent years, with a compound growth rate of up to 30% in recent years. In the past five years, the market share of the blood coagulation market in the rapidly developing IVD field has gradually increased from about 5% to about 10%.

The four-channel blood coagulation analyzer requires high instrument structure, optical parts and mechanical parts due to its special detection method. Imported brand instruments sell at a higher price. The quality of Meilun domestic brand instruments needs to be improved, and additional testing reagents are needed. The complex production process, short open bottle validity period, and high cost of imported reagents are many reasons, which put forward new requirements for manufacturers and suppliers of imported and domestic four-channel blood coagulation analyzers.

Currently, China's blood coagulation market has a capacity of approximately 2.7 billion yuan, and foreign-funded enterprises have great advantages in this field. At present, the coagulation instruments used in China are mainly imported instruments, and most of them are concentrated in Japan's Sysmex, France's Stago (Stago), and the United States Guojia Instrument Laboratory (IL, Werfen Group). In addition, Sekisui Japan and BE Germany have a small market share.

With the continuous development of society and economy, my country's medical system is facing major challenges. The development challenges of clinical laboratory laboratories are embodied in two aspects: On the one hand, Meilun’s medical expenditures continue to rise, requiring clinical laboratories to continuously reduce costs; on the other hand, with the improvement of people’s living standards, they pay more attention to their own medical care and are more accurate in testing. Sexual requirements continue to increase. For these reasons, the workload of laboratories continues to increase, and clinical testing laboratories are facing greater challenges.

With the continuous deepening of the hierarchical diagnosis and treatment policy in the past two years and the continuous promotion of related concepts such as community hospitals, the market for low-end four-channel four-channel blood coagulation analyzers will increase significantly; on the other hand, with the development of automated blood coagulation concepts Introduced, the high-end market will gradually integrate and upgrade, and continue to move towards automation.